Who makes Bromfenac 0.07% Oph Susp?

Bromfenac 0.07% Oph Susp is developed by Cindy Hutnik.

What development phase is Bromfenac 0.07% Oph Susp in?

Bromfenac 0.07% Oph Susp is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Bromfenac 0.07% Oph Susp

Cindy Hutnik · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Bromfenac 0.07% Oph Susp
Also known as	Bromfenac
Sponsor	Cindy Hutnik
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
NSAID vs Steroid in Trabeculectomy Wound Management (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bromfenac 0.07% Oph Susp CI brief — competitive landscape report
Bromfenac 0.07% Oph Susp updates RSS · CI watch RSS
Cindy Hutnik portfolio CI